T. Rowe Price Associates’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
Other funds holding PLX
T. Rowe Price Associates's PLX Position: Q3 2026 in Review
T. Rowe Price Associates held its Protalix BioTherapeutics (PLX) position steady in Q3 2026 at 53,478 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #3087.
T. Rowe Price Associates first reported a position in PLX in Q2 2023 and has held it in 10 quarters since. 107 funds tracked by Wall St. Rank hold PLX as of Q3 2026.
- T. Rowe Price Associates held 53,478 shares of Protalix BioTherapeutics worth $148K as of Q3 2026.
- T. Rowe Price Associates left its Protalix BioTherapeutics share count unchanged in Q3 2026.
- Protalix BioTherapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q3 2026, its #3087 holding.
- T. Rowe Price Associates first reported a position in Protalix BioTherapeutics in Q2 2023 and has held it in 10 quarters since.
- 107 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.
Based on T. Rowe Price Associates's 13F filing for Q3 2026, filed 16 Nov 2026.